Citations

Clear

281 citation(s) found for "Roberts, Lewis R".

AASLD guidelines for the treatment of hepatocellular carcinoma
Kulik, Laura , Roberts, Lewis R. , Zhu, Andrew X. , Murad, M. Hassan , Marrero, Jorge A. , Heimbach, Julie K. , Finn, Richard S. , Sirlin, Claude B. , Abecassis, Michael M. , Roberts, Lewis R , Murad, M Hassan

Mayo Clinic

Hepatology | January 28, 2017 | Volume: 67 | Issue: 1 | Pages: 358-380

10.1002/hep.29086 | PMID 28130846 Get It

Initiation of aberrant DNA methylation patterns and heterogeneity in precancerous lesions of human hepatocellular cancer
Hlady, Ryan A. , Zhou, Dan , Puszyk, William, Roberts, Lewis R. , Liu, Chen , Robertson, Keith D. , Roberts, Lewis R , Robertson, Keith D , Liu, Chen

Mayo Clinic

Epigenetics | January 6, 2017 | Volume: 12 | Issue: 3 | Pages: 215-225

10.1080/15592294.2016.1277297 | PMID 28059585 Get It

Determination of hepatitis B phenotype using biochemical and serological markers
Bisceglie, Adrian M. Di , Lombardero, M. , Teckman, Jeffrey , Roberts, Lewis R. , Janssen, Harry L.A. , Belle, Steven H., Hoofnagle, Jay H., Chang, Kyong‐Mi , Ghany, Marc G. , Khalili, Mandana , Roberts, Lewis R , Chang, Kyong-Mi , Khalili, Mandana

Mayo Clinic

Journal of Viral Hepatitis | December 5, 2016 | Volume: 24 | Issue: 4 | Pages: 320-329

10.1111/jvh.12643 | PMID 27917600 Get It

AbstractThe aim of this study was to assess the validity of categorization of chronic hepatitis B viral infection into stages or phases based upon measures of disease activity and viral load, assuming these phenotypes will be useful for prognostication and determining the need for antiviral therapy. We assessed the phenotype of hepatitis B of 1,390 adult participants enrolled in the Hepatitis B Research Network Cohort Study, using a computer algorithm. Only 4% were immune tolerant, while 35% had chronic hepatitis B (18% e antigen positive and 17% e antigen negative) while 23% were inactive carriers. Strikingly, 38% of participants did not fit clearly into any one of these groups and were considered indeterminant. The largest subset of indeterminants had elevated serum aminotransferases with low levels of HBV DNA (less than 10,000 iu/mL). Subsequent determination of hepatitis B phenotype on the next available laboratory tests showed that 64% remained indeterminant. These findings call into question the validity of conventional staging of hepatitis B, in large part because of the substantial proportion of patients who do not fit readily into one of the usual stages or phases. Further studies are needed of the indeterminant category of chronic hepatitis B viral infection, including assessments of whether patients in this group are perhaps in transition to another phase or if they are a distinct phenotype with a need to assess liver disease severity and need for antiviral therapy. (ClinicalTrials.gov identifier NCT01263587).
Vascularized appendicular lymph node transfer for treatment of extremity lymphedema: A case report
Ciudad, Pedro , Manrique, Oscar J. , Date, Shivprasad , Chang, Wei‐Ling , Nicoli, Fabio , Sapountzis, Stamatis , Cheng, Hsu‐Tang , Agko, Mouchammed , Chen, Hung‐Chi , Roberts, Lewis R. , Chen, Hung‐Chi , Roberts, Lewis R , Cheng, Hsu-Tang , Mouchammed, Agko

Mayo Clinic

Microsurgery | December 2, 2016 | Volume: 38 | Issue: 5 | Pages: 553-557

10.1002/micr.30134 | PMID 27911477 Get It

AbstractVascularized lymph node transfer has demonstrated promising results for the treatment of extremity lymphedema. In an attempt to find the ideal donor site, several vascularized lymph nodes have been described. Each has a common goal of decreasing morbidity and avoiding iatrogenic lymphedema while obtaining good clinical results. Herein, we present the preliminary clinical outcomes of an intra‐abdominal lymph node flap option based on the appendicular artery and vein used for the treatment of extremity lymphedema. A 62 year‐old woman with moderate lower extremity lymphedema, on chronic antibiotics because of recurrent infections and unsatisfactory outcomes after conservative treatment underwent a vascularized appendicular lymph node (VALN) transfer. At a follow‐up of 6 months, the reduction rate of the limb circumference was 17.4%, 15.1%, 12.0% and 9% above the knee, below the knee, above the ankle and foot respectively. In addition, no further episodes of infection or other complications were reported after VALN transfer. Postoperative lymphoscintigraphy demonstrated that the VALN flap was able to improve the lymphatic drainage of the affected limb. According to our findings, the use of VALN transfer minimizes donor‐site morbidity, avoids iatrogenic lymphedema and may provide a strong clearance of infection because of the strong immunologic properties of the appendiceal lymphatic tissue in selected patients. Despite these promising results, further research with larger number of patients and longer follow‐ up is needed.
Transcriptional Induction of Periostin by a Sulfatase 2–TGFβ1–SMAD Signaling Axis Mediates Tumor Angiogenesis in Hepatocellular Carcinoma
Chen, Gang , Nakamura, Ikuo , Dhanasekaran, Renumathy , Iguchi, Eriko , Tolosa, Ezequiel J. , Romecín, Paola , Vera, Renzo E., Almada, Luciana L. , Miamen, Alexander G., Chaiteerakij, Roongruedee , Zhou, Mengtao , Moser, Catherine D., Han, Shaoshan , Hu, Chunling , Banini, Bubu A. , Oseini, Abdul M., Fang, Yong , Yang, Dongye , Shaleh, Hassan M., Wang, Shaoqing , Wu, Dehai, Song, Tao , Lee, Ju‐Seog , Thorgeirsson, Snorri S., Chevet, Éric , Shah, Vijay H. , Fernández-Zapico, Martín E. , Roberts, Lewis R. , Romecin, Paola A, Asiedu, Michael K. , Chen, Yichun, Nakamura, Ikuo, Chaiteerakij, Roongruedee , Chen, Yi‐Chun , Roberts, Lewis R , Dhanasekaran, Renumathy , Hu, Chunling , Chen, Gang , Chevet, Eric

Mayo Clinic

Cancer Research | November 21, 2016 | Volume: 77 | Issue: 3 | Pages: 632-645

10.1158/0008-5472.can-15-2556 | PMID 27872089 Get It

Abstract Existing antiangiogenic approaches to treat metastatic hepatocellular carcinoma (HCC) are weakly effectual, prompting further study of tumor angiogenesis in this disease setting. Here, we report a novel role for sulfatase 2 (SULF2) in driving HCC angiogenesis. Sulf2-deficient mice (Sulf2 KO) exhibited resistance to diethylnitrosamine-induced HCC and did not develop metastases like wild-type mice (Sulf2 WT). The smaller and less numerous tumors formed in Sulf2 KO mice exhibited a markedly lower microvascular density. In human HCC cells, SULF2 overexpression increased endothelial proliferation, adhesion, chemotaxis, and tube formation in a paracrine fashion. Mechanistic analyses identified the extracellular matrix protein periostin (POSTN), a ligand of αvβ3/5 integrins, as an effector protein in SULF2-induced angiogenesis. POSTN silencing in HCC cells attenuated SULF2-induced angiogenesis and tumor growth in vivo. The TGFβ1/SMAD pathway was identified as a critical signaling axis between SULF2 and upregulation of POSTN transcription. In clinical HCC specimens, elevated levels of SULF2 correlated with increased microvascular density, POSTN levels, and relatively poorer patient survival. Together, our findings define an important axis controlling angiogenesis in HCC and a mechanistic foundation for rational drug development. Cancer Res; 77(3); 632–45. ©2016 AACR.
High fat diet and exercise lead to a disrupted and pathogenic DNA methylome in mouse liver
Zhou, Dan , Hlady, Ryan A. , Schafer, Marissa , White, Thomas A. , Liu, Chen , Choi, Jeong‐Hyeon , Miller, Jordan D. , Roberts, Lewis R. , LeBrasseur, Nathan K. , Robertson, Keith D. , Schafer, Marissa J, Roberts, Lewis R , Robertson, Keith D , LeBrasseur, Nathan K , Schafer, Marissa J , Liu, Chen , Miller, Jordan

Mayo Clinic

Epigenetics | November 18, 2016 | Volume: 12 | Issue: 1 | Pages: 55-69

10.1080/15592294.2016.1261239 | PMID 27858497 Get It

Reply
Chaiteerakij, Roongruedee , Roberts, Lewis R. , Roberts, Lewis R , Choi, Jonggi , Chaiteerakij, Roongruedee

Mayo Clinic

Hepatology | November 5, 2016 | Volume: 65 | Issue: 4 | Pages: 1422-1423

10.1002/hep.28922 | PMID 28032640 Get It

Novel Deleterious Dihydropyrimidine Dehydrogenase Variants May Contribute to 5‐Fluorouracil Sensitivity in an East African Population
Elraiyah, Tarig, Jerde, Calvin R. , Shrestha, Shikshya , Wu, Rongmei , Nie, Q, Giama, NH, Sarangi, Vivekananda , Roberts, Lewis R. , Offer, SM, Diasio, RB, Offer, Steven M. , Nie, Qian , Wu, R, Nie, Q, Roberts, Lewis R , Offer, Steven M

Mayo Clinic

Clinical Pharmacology & Therapeutics | October 13, 2016 | Volume: 101 | Issue: 3 | Pages: 382-390

10.1002/cpt.531 | PMID 27727460 Get It

Clinical studies have identified specific genetic variants in dihydropyrimidine dehydrogenase (DPD; DPYD gene) as predictors of severe adverse toxicity to the commonly used chemotherapeutic 5‐fluorouracil (5‐FU); however, these studies have focused on European and European‐American populations. Our laboratory recently demonstrated that additional variants in non‐European haplotypes are predictive of 5‐FU toxicity. The objective of this study was to identify potential risk variants in an understudied East African population relevant to our institution's catchment area. The DPYD protein‐coding region was sequenced in 588 individuals of Somali or Kenyan ancestry living in central/southeast Minnesota. Twelve novel nonsynonymous variants were identified, seven of which significantly decreased DPD activity in vitro. The commonly reported toxicity‐associated variants, *2A, D949V, and I560S, were not detected in any individuals. Overall, this study demonstrates a critical limitation in our knowledge of pharmacogenetic predictors of 5‐FU toxicity, which has been based on clinical studies conducted in populations of limited diversity.
Increased Prevalence of Metabolic Risk Factors in Asian Americans With Hepatocellular Carcinoma
Kutsenko, Alina , Ladenheim, Maya R., Kim, Nathan G. , Nguyen, Pauline, Chen, Vincent , Jayasekera, Channa R. , Yang, Ju Dong , Kumari, Radhika, Roberts, Lewis R. , Nguyen, Mindie H. , Yang, Ju Dong , Roberts, Lewis R , Chen, V L

Mayo Clinic

Journal of Clinical Gastroenterology | September 16, 2016 | Volume: 51 | Issue: 4 | Pages: 384-390

10.1097/mcg.0000000000000689 | PMID 27636408 Get It

Background: We used metabolic risk factors to estimate the prevalence and clinical significance of nonalcoholic fatty liver disease in Asian Americans with hepatocellular carcinoma (HCC). Methods: This is a retrospective cohort study of 824 consecutive Asian HCC patients at Stanford University Medical Center from 1998 to 2015. Patients were subdivided as: Chinese, other East Asian (Japanese and Korean), South East Asian (Vietnamese, Thai, and Laotian), Maritime South East Asian (MSEA: Malaysian, Indonesian, Filipino, and Singaporean), and South West Asian (Indian, Pakistani, and Middle Eastern). Metabolic risk factors studied were body mass index, hypertension, type II diabetes, and hyperlipidemia. Results: Most patients were male (76%) with mean age 63 years. Metabolic risk factors were highly prevalent on presentation and increased over time (P<0.001), as did the prevalence of cryptogenic HCC (P<0.004). Compared with other Asian subgroups, MSEAs had the highest body mass index (26.3) and higher rates of type II diabetes (44% vs. 23% to 35%, P=0.004), hypertension (59% vs. 38% to 55%, P=0.04), and cryptogenic HCC (15% vs. 4% to 10%, P=0.01). They were more likely to be symptomatic on presentation (44% vs. 32% to 58%, P=0.07), less likely to present within Milan criteria (34% vs. 35% to 63%, P<0.0001), and trended toward decreased 10-year survival rates compared with other ethnic subgroups (9% vs. 25% to 32%, P=0.07). Conclusions: Metabolic risk factors were increasingly prevalent among Asian Americans with HCC. MSEAs, who had the highest incidence of these risk factors, had more advanced tumor stage and trended toward worse survival.
Reply
Roayaie, Sasan , Sherman, Morris , Roberts, Lewis R. , Roberts, Lewis R

Mayo Clinic

Hepatology | September 12, 2016 | Volume: 64 | Issue: 6 | Pages: 2258-2259

10.1002/hep.28807 | PMID 27618669 Get It